BioGenes and FyoniBio Combine Their Scientific Expertise and Cooperate on Pharmacokinetic and Immunogenicity Analyses
- This collaboration covers a broad range of services, from antibody development to the analysis of clinical samples
- The individual expertise of each company makes them ideal partners
- The first customer projects are expected to start in the next couple of weeks
BERLIN, Germany, August 24, 2021 / B3C newswire / -- Pharmacokinetic and immunogenicity projects can be both diverse and complex, involving work packages from antibody generation and production to the analysis of clinical samples with validated assays. At the end of June, an agreement was signed by BioGenes GmbH and FyoniBio (1), thanks to which pharmaceutical and biotech companies can now obtain these services from a single source and thus rely on the long-standing, complementary expertise of both companies.
Due to their great experience, both BioGenes and FyoniBio ensure that projects are handled with maximized efficiency. BioGenes, as an expert in antibody production and ELISA setup, takes care of the first steps of the project, while FyoniBio, a specialist in bioassay development and validation for analysis of clinical samples, uses their expertise to transfer the assay to the MSD2 (2) platform for analyzing clinical samples under “good clinical and laboratory practice” (GCLP). Specialists at both Berlin-based companies always guarantee comprehensive project management.
"We are very pleased that the cooperation with FyoniBio has now officially started," said Dr. Alexander Knoll, CEO of BioGenes GmbH. "We are convinced that our complete package for high-quality and customized immunological tests for new biological compounds and clinical samples offers an enormous added value for customers."
"Both companies want to provide the perfect service for each customer. In this respect, as well as regarding scientific excellence in their respective fields, the two companies complement each other very well," added Dr. Hans Baumeister, Service Division Manager at FyoniBio. "We are looking forward to the first joint projects.”
BioGenes is a highly specialized and experienced partner for challenging and customized antibody and immunoassay development projects with a special focus on assays for quality control, diagnostics, and the development and testing of new biological therapeutics.
The Berlin-based company, which has been ISO certified since 1999, operates worldwide and maintains long-term business relationships with biotech and pharmaceutical companies, including eight of the world's ten largest pharmaceutical companies. The company has been rated by a leading auditing firm as one of the world's most important companies in the field of Host Cell Protein (HCP) analysis.
FyoniBio is the newly formed, ISO 9001 certified contract development division (CDO) and clinical lab of Glycotope GmbH, offering 20 years of experience in services related to biopharmaceutical development. Located in Berlin, their analytical/clinical lab is specialized in the development and validation of PK, biomarkers, immunogenicity assays and complex bioassays for analysis of (pre-) clinical samples, if necessary, under GCLP. The CDO department provides a one-stop shop for clone development based on CHO and their own GEX® technology to process development ready for transfer to the GMP facility of the customer`s choice. Their knowledge of glycobiology is outstanding, especially regarding analytics and cell biology.
Head of Marketing/Communications
(1) FyoniBio ist the service branch of Glycotope GmbH
(2) 2Meso Scale Discovery LLC. (MSD)
Keywords: Laboratories; Immune System Phenomena; Pharmacokinetics; Immunoassay; Enzyme-Linked Immunosorbent Assay; Immunologic Tests; Antibodies; Antibody Formation; Biological Assay; Quality Control; Pharmaceutical Preparations; Biotechnology; Germany
Published by B3C newswire